Zhongjin: Maintains Outperform rating on Woorld Biotech-B (01477.HK), raises target price to HK$10.16.

The Zhitong Financial APP learned that Zhongjin released a research report stating that it maintains its profit forecasts for Eurocell Vision Bio-B (01477.HK) in 2025/2026. The bank maintains an outperform industry rating, considering the recent sector valuation pivot, the bank has raised its DCF target price by 35.5% to 10.16 Hong Kong dollars, with 3.4% upward space compared to the current stock price. The company announced its performance for the first half of 2025: revenue of 294 million yuan, a year-on-year increase of 75.4%; a loss of 132 million yuan during the period, a narrowing compared to the same period in 2024, in line with the bank's expectations.